| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-04-11 | Zambon (Italy) Valeo Pharma (Canada) | Xadago™ (safinamide) | add-on therapy to a stable dose of a single dopamine agonist in early Parkinson’s disease patients add-on therapy to levodopa alone or in combination with other Parkinson’s disease treatments in mid-to late stage Parkinson’s disease patients | commercialisation | Neurodegenerative diseases | Commercialisation agreement |
| 2017-04-11 | Takeda Pharmaceutical (Japan) NuBiyota (USA - NJ) | Microbial Ecosystem Therapeutic products | gastrointestinal diseases | development | Gastrointestinal diseases | Development agreement |
| 2017-04-10 | XBiotech (USA - TX) | nomination | Cancer - Oncology | Nomination | ||
| 2017-04-07 | Takeda Pharmaceutical (Japan) PRA Health Sciences (USA - NC) | services contract | Services contract | |||
| 2017-04-05 | Newron Pharmaceuticals (Italy) Meiji Seika Pharma (Japan) Eisai (Japan) | safinamide | Parkinson's disease | R&D - research - development - licensing - commercialisation | Neurodegenerative diseases - CNS diseases | Licensing agreement |
| 2017-04-05 | AstraZeneca (UK) Heptares Therapeutics (UK), a subsidiary of Sosei Group (Japan) | HTL-1071 (AZD4635) and potential additional A2A receptor-blocking compounds | licensing - development - manufacturing - production - commercialisation | Cancer - Oncology | Milestone | |
| 2017-04-05 | Takeda Pharmaceutical (Japan) Finch Therapeutics (USA - MA) | FIN-524 | inflammatory bowel disease | licensing - development - commercialisation | Licensing agreement | |
| 2017-04-05 | Allecra Therapeutics (Germany - France) | chairman of the board of directors, chief medical officer | nomination | Infectious diseases | Nomination | |
| 2017-04-04 | MDxHealth (Belgium) Ghent University (Belgium) | cancer biomarker visualization technology | prostate cancer, bladder cancer | collaboration | Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2017-04-04 | UCB (Belgium) Q-State Biosciences (USA - MA) | novel therapeutics for genetically defined subtypes of childhood epilepsy that present with substantial morbidity | epilepsy | collaboration - R&D - research | Neurological diseases - CNS diseases | Collaboration agreement |
| 2017-04-04 | Alder Biopharmaceuticals (USA - WA) | nomination | CNS diseases - Neurological diseases | Nomination | ||
| 2017-04-04 | Amag Pharmaceuticals (USA - MA) Endoceutics (Canada) | Intrarosa™ (prasterone) | moderate-to-severe dyspareunia | licensing | Women health | Licensing agreement |
| 2017-04-03 | Merrimack Pharmaceuticals (USA - MA) | restructuring | Cancer - Oncology | Restructuring | ||
| 2017-04-03 | Aveo Oncology (USA - MA) CANbridge Life Sciences (China) | AV-203 | esophageal squamous cell cancer | collaboration, licensing | Cancer - Oncology | Milestone |
| 2017-04-03 | Sarepta Therapeutics (USA - MA) | chief medical officer | nomination | Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination | |
| 2017-04-02 | BMS (USA - NY) Incyte (USA - DE) | epacadostat and nivolumab | first-line non-small cell lung cancer, first-line head and neck cancer, melanoma | clinical research | Clinical research agreement | |
| 2017-03-31 | Incyte (USA - DE) Merck&Co (USA - NJ) | epacadostat and Keytruda® (pembrolizumab) | advanced or metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), squamous cell carcinoma of the head and neck (SCCHN) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-03-31 | Calypso Biotech (Switzerland) EA Pharma (Japan) | CALY-001 | inflammatory bowel disease | licensing | Digestive diseases - Gastrointestinal diseases - Inflammatory diseases | Licensing agreement |
| 2017-03-31 | Veloxis Pharmaceuticals (Denmark) Taiba Healthcare (Sultanate of Oman) | Envarsus® XR (tacrolimus) | prevention of organ rejection in kidney transplant patients | licensing - commercialisation - distribution | Transplantation - Renal diseases - Kidney diseases | Licensing agreement |
| 2017-03-30 | Takeda Pharmaceutical (Japan) Center for iPS Cell Research and Application at Kyoto University (CiRA) (Japan) | clinical applications of induced pluripotent stem cells | heart failure, diabetes mellitus, neurological disorders, cancer | collaboration | Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Neurological diseases | Collaboration agreement |
